FDA clears Motivista for negative symptoms in schizophrenia
Click Therapeutics' Motivista, a prescription digital therapeutic for negative symptoms of schizophrenia, received FDA 510(k) clearance. It is administered via smartphone as an adjunct to outpatient therapy. The company reported a 6.8-point improvement in negative symptom severity in a phase III study, compared to 4.2 in the control group. Motivista is not designed for acute symptoms or as a replacement for clinician-managed care.
How this was made
The 30-second read
Why it matters
The clearance creates a new market segment, potentially expanding Click's addressable market and revenue, while also setting a precedent for digital therapeutics in psychiatry.
Market read
Regulatory approval for a novel digital therapeutic could drive share price appreciation and influence the broader digital health sector.
What to watch
State Medicaid coverage decisions and payer reimbursement policies could materially affect commercial uptake.
Background
Click Therapeutics announced FDA 510(k) clearance for Motivista, the first prescription digital therapeutic targeting negative symptoms of schizophrenia, delivered via a smartphone app.
Ticker impact
Click Therapeutics received FDA 510(k) clearance for Motivista, a digital therapeutic for negative symptoms of schizophrenia.
likely upward pressure as investors price in the first FDA-authorized therapy for schizophrenia negative symptoms
Clearance is a material regulatory milestone for a biotech with no prior approved product in this indication, creating a first-mover advantage.
Market effects
May boost interest in digital therapeutics and other mental‑health biotech firms.
U.S. biotech sector could see modest uplift.
Limited to companies developing FDA‑cleared digital health products.
Counterpoint
If adoption is slow due to reimbursement hurdles, the stock could face disappointment despite clearance.
Key entities
- CompanyClick Therapeutics
Developer of Motivista, now FDA-cleared.
- Regulatory AgencyFDA
Granted 510(k) clearance for Motivista.
